Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Drug-Eluting Stents versus Bare-Metal Stents in Taiwanese Patients with Acute Coronary Syndrome: An Outcome Report of a Multicenter Registry.

Lai CC, Yip HK, Lin TH, Wu CJ, Lai WT, Liu CP, Chang SC, Mar GY.

Acta Cardiol Sin. 2014 Nov;30(6):553-64.

2.

Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis.

Valgimigli M, Sabaté M, Kaiser C, Brugaletta S, de la Torre Hernandez JM, Galatius S, Cequier A, Eberli F, de Belder A, Serruys PW, Ferrante G.

BMJ. 2014 Nov 4;349:g6427. doi: 10.1136/bmj.g6427.

3.

Drug-eluting stents and acute myocardial infarction: A lethal combination or friends?

Otsuki S, Sabaté M.

World J Cardiol. 2014 Sep 26;6(9):929-38. doi: 10.4330/wjc.v6.i9.929. Review.

4.
5.

Risks and Benefits of Thrombolytic, Antiplatelet, and Anticoagulant Therapies for ST Segment Elevation Myocardial Infarction: Systematic Review.

Nascimento BR, de Sousa MR, Demarqui FN, Ribeiro AL.

ISRN Cardiol. 2014 Feb 6;2014:416253. doi: 10.1155/2014/416253. eCollection 2014. Review.

6.

The use of drug-eluting stents in acute myocardial infarction - is the battle coming to an end? From despair to acceptance.

Kübler P, Reczuch K.

Postepy Kardiol Interwencyjnej. 2013;9(1):50-4. doi: 10.5114/pwki.2013.34028. Epub 2013 Mar 21. Review.

7.

Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register.

Mrdovic I, Savic L, Lasica R, Krljanac G, Asanin M, Brdar N, Djuricic N, Marinkovic J, Perunicic J.

Eur Heart J Acute Cardiovasc Care. 2014 Mar;3(1):56-66. doi: 10.1177/2048872613514013. Epub 2013 Nov 21.

8.

The role of the interventional cardiologist in selecting antiplatelet agents in acute coronary syndromes: a 10-question strategy.

Schiele F, Meneveau N.

Eur Heart J Acute Cardiovasc Care. 2012 Jun;1(2):170-6. doi: 10.1177/2048872612450576.

9.
10.

Integrin αIIbβ3: from discovery to efficacious therapeutic target.

Bledzka K, Smyth SS, Plow EF.

Circ Res. 2013 Apr 12;112(8):1189-200. doi: 10.1161/CIRCRESAHA.112.300570. Review.

11.

Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?

Berger PB, Williams JB, Hasselblad V, Chiswell K, Pieper KS, Califf RM.

J Interv Cardiol. 2013 Apr;26(2):123-30. doi: 10.1111/j.1540-8183.2013.12020.x. Epub 2013 Feb 5.

12.

Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review.

Leonardi S, Armstrong PW, Schulte PJ, Ohman EM, Newby LK.

Eur Heart J. 2013 Mar;34(12):894-902d. doi: 10.1093/eurheartj/eht003. Epub 2013 Jan 25. Review.

13.

High Bolus Tirofiban vs Abciximab in Acute STEMI Patients Undergoing Primary PCI - The Tamip Study.

Balghith MA.

Heart Views. 2012 Jul;13(3):85-90. doi: 10.4103/1995-705X.102145.

14.

Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty.

Guo J, Xu M, Xi Y.

Tex Heart Inst J. 2012;39(1):99-103. Review.

15.

Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban.

Campo G, Fileti L, Valgimigli M, Marchesini J, Scalone A, Ferrari R.

J Blood Med. 2010;1:61-9. doi: 10.2147/JBM.S7236. Epub 2010 May 10.

16.

Intra-arterial tirofiban infusion for partial recanalization with stagnant flow in hyperacute cerebral ischemic stroke.

Baik SK, Oh SJ, Park KP, Lee JH.

Interv Neuroradiol. 2011 Dec;17(4):442-51. Epub 2011 Dec 16.

17.

Percutaneous treatment in acute coronary syndromes.

Alegría-Barrero E, Moreno R.

World J Cardiol. 2011 Oct 26;3(10):315-21. doi: 10.4330/wjc.v3.i10.315.

18.

GPIIb/IIIa Receptor Antagonism Using Small Molecules Provides no Additive Long-Term Protection after Percutaneous Coronary Intervention as Compared to Clopidogrel Plus Aspirin.

Schiariti M, Saladini A, Papalia F, Grillo P, Nesta C, Cuturello D, Missiroli B, Puddu PE.

Open Cardiovasc Med J. 2010 Jul 20;4:151-6. doi: 10.2174/1874192401004010151.

19.

Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome.

Pham SV, Pham PC, Pham PM, Miller JM, Pham PT, Pham PA.

Drug Des Devel Ther. 2010 Sep 7;4:203-20. doi: 10.2147/DDDT.S12056. Review.

20.

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention.

Vergara-Jimenez J, Tricoci P.

Vasc Health Risk Manag. 2010 Mar 3;6:39-45. Review.

Supplemental Content

Support Center